Cart
sales@molnova.com
LXW7
CAS No. 1313004-77-1
LXW7( —— )
Catalog No. M22343 CAS No. 1313004-77-1
LXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | In Stock |
|
| 5MG | 268 | In Stock |
|
| 10MG | 408 | In Stock |
|
| 25MG | 672 | In Stock |
|
| 50MG | 945 | In Stock |
|
| 100MG | 1278 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLXW7
-
NoteResearch use only, not for human use.
-
Brief DescriptionLXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.
-
DescriptionLXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.
-
In VitroLXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells.LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery. LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand.
-
In VivoLXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines. Animal Model:Male Sprague-Dawley rats (250-280 g) subjected to middle cerebral artery occlusion (MCAO)Dosage:100 μg/kg Administration:Intravenous injection Result:Infarct volumes and BWC were significantly lower compared to those in the MCAO+PBS (control) group.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorαVβ3 integrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1313004-77-1
-
Formula Weight820.89
-
Molecular FormulaC29H48N12O12S2
-
Purity>98% (HPLC)
-
SolubilityH2O
-
SMILESNC(=O)[C@H]1CSSC[C@@H](N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](C(C)C)C(=O)N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Lifitegrast sodium
Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.
-
Echistatin, α1 isofo...
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.
-
AJM300
AJM300 (AJM 300, AJM-300) is a novel potent, selective, oraaly available alpha 4 integrin antagonist fortreatment of active ulcerative colitis.
